Crossject is revolutionizing needle free injection

Paragraphes

Crossject is revolutionizing the administration of well-established treatments with its needle-free auto-injector ZENEO®. The prefilled, single-use device propels the medicine through the skin in less than a tenth of a second. Crossject currently has seven solutions in advanced stages of development, six of which are for emergency situations.  

Zeneo illustration

 

Our news

Image de l'actualité
Crossject will attend

Injecta Summit - June 27-28, 2024 -Barcelona

Résumé de l'actualité

Henri Bodeau, Business Development Manager, will be Keynote Speaker at the Summit

Image de l'actualité
Business meeting

CPhI North America

Résumé de l'actualité

May 7-9, 2024,  Philadelphia

Image
ZENEO auto-injecteur

Financial news: Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

Sommaire ou résumé

Dijon, France, July 15th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024.